[go: up one dir, main page]

WO2005095972A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb) - Google Patents

Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb) Download PDF

Info

Publication number
WO2005095972A3
WO2005095972A3 PCT/EP2005/002336 EP2005002336W WO2005095972A3 WO 2005095972 A3 WO2005095972 A3 WO 2005095972A3 EP 2005002336 W EP2005002336 W EP 2005002336W WO 2005095972 A3 WO2005095972 A3 WO 2005095972A3
Authority
WO
WIPO (PCT)
Prior art keywords
etb
disorders
therapeutics
diagnostics
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/002336
Other languages
French (fr)
Other versions
WO2005095972A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2005095972A2 publication Critical patent/WO2005095972A2/en
Publication of WO2005095972A3 publication Critical patent/WO2005095972A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human ETB which is associated with the cardiovascular disorders, neurological disorders, urological disorders, respiratory diseases and inflammatory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, neurological disorders, urological disorders, respiratory diseases and inflammatory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of ETB as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/002336 2004-03-19 2005-03-05 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb) Ceased WO2005095972A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04006665 2004-03-19
EP04006665.6 2004-03-19

Publications (2)

Publication Number Publication Date
WO2005095972A2 WO2005095972A2 (en) 2005-10-13
WO2005095972A3 true WO2005095972A3 (en) 2006-04-06

Family

ID=34961193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002336 Ceased WO2005095972A2 (en) 2004-03-19 2005-03-05 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb)

Country Status (1)

Country Link
WO (1) WO2005095972A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501680A1 (en) * 2010-02-23 2012-11-05 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
FR2965810B1 (en) * 2010-10-06 2012-12-28 Commissariat Energie Atomique ANTAGONIST ANTIBODY OF ENDOTHELIN RECEPTOR B-SUBTYPE B AND USES THEREOF
WO2013152076A1 (en) * 2012-04-04 2013-10-10 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hypertension
JP2015529656A (en) 2012-08-02 2015-10-08 ジェネンテック， インコーポレイテッド Anti-ETBR antibodies and immune complexes
CA2879665A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080960A2 (en) * 2001-04-05 2002-10-17 Medical Research Council Treatment of neuropathologies associated with expression of tnf-alpha
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2003039539A2 (en) * 2001-11-09 2003-05-15 Merck Patent Gmbh Use of endothelin receptor antagonists in the treatment of tumour diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080960A2 (en) * 2001-04-05 2002-10-17 Medical Research Council Treatment of neuropathologies associated with expression of tnf-alpha
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2003039539A2 (en) * 2001-11-09 2003-05-15 Merck Patent Gmbh Use of endothelin receptor antagonists in the treatment of tumour diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARPENTER TODD ET AL: "Endothelin B receptor deficiency predisposes to pulmonary edema formation via increased lung vascular endothelial cell growth factor expression.", CIRCULATION RESEARCH, vol. 93, no. 5, 5 September 2003 (2003-09-05), pages 456 - 463, XP002339617, ISSN: 0009-7330 *
KOHZUKI M ET AL: "ENDOTHELIN RECEPTORS IN ISCHEMIC RAT BRAIN AND ALZHEIMER BRAIN", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, NEW YORK, NY, US, vol. 26, no. SUPPL 3, 1995, pages S329 - S331, XP009023544, ISSN: 0160-2446 *
LEHRKE INGO ET AL: "Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 12, no. 11, November 2001 (2001-11-01), pages 2321 - 2329, XP002339616, ISSN: 1046-6673 *
OUE T ET AL: "Altered endothelin-3 and endothelin-B receptor mRNA expression in Hirschsprung's disease.", JOURNAL OF PEDIATRIC SURGERY. AUG 1999, vol. 34, no. 8, August 1999 (1999-08-01), pages 1257 - 1260, XP009052047, ISSN: 0022-3468 *
YAGAMI T ET AL: "EFFCTS OF ENDOTHELIN B RECEPTOR AGONISTS ON AMYLOID BETA PROTEIN (25-35)-INDUCED NEURONAL CELL DEATH", BRAIN RESEARCH, AMSTERDAM, NL, vol. 948, no. 1/2, 6 September 2002 (2002-09-06), pages 72 - 81, XP001156395, ISSN: 0006-8993 *

Also Published As

Publication number Publication date
WO2005095972A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2005095972A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)
WO2004086034A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2005003762A3 (en) Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 2 (snsr2)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004082566A3 (en) Diagnostics and therapeutics for diseases associated with complement component 3a receptor 1 (c3ar1)
WO2004082569A3 (en) Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2004097405A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor h7tba62 (h7tba62)
WO2005040826A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 64 (gpr64)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase